Table 2.

Outcomes of patients receiving PO cyclophosphamide compared to IV cyclophosphamide

	PO cyclophosphamide group n (%)	IV cyclophosphamide group n (%)	Unadjusted HR/OR for PO cyclophosphamide	Adjusted HR/OR for PO cyclophosphamidea	P value (for adjusted HR/OR)
Mortality	17 (30%)	5 (9%)	3.9 (1.4–10.4)	1.9 (0.3–12.0)	P = 0.47
Relapse	14 (25%)	24 (42%)	0.5 (0.3–1.0)	1.0 (0.4–2.6)	P = 1.00
Neutropenia	9 (16%)	0 (0%)	–	–	P = 0.003*
Infection requiring admission	16 (28%)	9 (16%)	2.0 (0.8–5.0)	2.2 (0.6–8.7)	P = 0.24

Hazard ratio (HR) for mortality and relapse rates during the whole follow-up period was calculated using Cox regression. Odds ratio (OR) for neutropenia or infection requiring hospital admission within 1 year after diagnosis was calculated using logistic regression

*P value from Fisher’s exact test (unadjusted for confounders)

^aAdjusted for age category, sex, eGFR category and ANCA type